Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications

Júnior, Roberto Lúcio Muniz; Godói, Isabella Piassi Dias; Reis, Edna Afonso; Garcia, Marina Morgado; Guerra, Augusto Afonso; Godman, Brian; Ruas, Cristina Mariano

doi:10.1080/14737167.2019.1552136

Cited by 22 publications

(45 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, different methods may be needed to fully incorporate the benefits and value of new medicines for cancer into future pricing considerations given affordability constraints that exist within countries, especially LMICs. • Willingness-to-pay studies have been conducted among the public in Brazil to help establish possible prices for new vaccines serving as potential benchmarks [130,131] Supply security Information on potential volumes and producers (for multi-sourced products) are needed to maintain competition and supply for specific products, which such data seen as feasible to collect. This is because supply shortages are becoming a key issue across countries [132] [119].…”

Section: Buyers (Including Health Authorities and Patients)mentioning

confidence: 99%

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Godman

Hill

Simoens

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

Self Cite

View full text Add to dashboard Cite

Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.

show abstract

Section: Buyers (Including Health Authorities and Patients)mentioning

confidence: 99%

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Godman

Hill

Simoens

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Few studies have addressed the acceptability of a hypothetical ZIKV vaccine should it become available in the near future [15,[23][24][25][26][27][28][29][30][31][32], and their geographic distribution is not representative of the populations at risk. The majority of studies were performed in the USA, four in South East Asia, and only two in South America, in Brazil and Guatemala.…”

Section: Introductionmentioning

confidence: 99%

Acceptability of a Hypothetical Zika Vaccine among Women from Colombia and Spain Exposed to ZIKV: A Qualitative Study

et al. 2020

View full text Add to dashboard Cite

Zika virus (ZIKV) can cause pregnancy loss and congenital Zika syndrome, among other poor health outcomes. The ZIKV epidemic in 2015–2017 disproportionately affected pregnant women in poor-resource settings. We aimed to understand perceptions and attitudes towards a hypothetical ZIKV vaccine, women’s willingness to be vaccinated, and potential barriers and facilitators for vaccine acceptance in 1) migrant women living in Spain who travelled to their countries of origin and were diagnosed with ZIKV infection during pregnancy, and their healthcare providers, and 2) women living in Colombia who delivered a child with microcephaly. An exploratory qualitative study based on phenomenology and grounded theory was conducted. Data were collected through in-depth, paired and semi-structured interviews. Overall, women from both sites were willing to receive a hypothetical ZIKV vaccine. However, some expressed concerns of being vaccinated during pregnancy, yet they would accept it if the vaccine was recommended by a healthcare professional they trust. Main fears towards vaccination were related to vaccine safety and potential adverse effects on child’s health. Women reported feeling hesitant to participate in a ZIKV vaccine trial. These results may contribute to guiding the effective delivery of future ZIKV vaccines among populations most at risk and particularly vulnerable.

show abstract

“…Existing literature on acceptability of novel vaccines has tended to focus on a handful of topics: a future HIV vaccine, the introduction of the HPV vaccine series, and willingness-to-pay assessments of infectious diseases. [8][9][10][11][12][13][14] While a narrow focus on a specific vaccine is practical during vaccine development, assessing novel vaccine acceptability from the more general perspective of vaccine hesitancy is overdue.…”

mentioning

confidence: 99%

Willingness of Black and White Adults to Accept Vaccines in Development: An Exploratory Study Using National Survey Data

et al. 2020

View full text Add to dashboard Cite

Purpose: Explore acceptability of vaccines in development: cancer, Type II diabetes, Alzheimer’s disease, Lyme disease, Ebola, and obesity. Research questions: To what extent does acceptability vary by vaccine type? To what extent does acceptability of vaccines in development vary by race and other key demographics? To what extent are general vaccine hesitancy and key demographics associated with acceptability of vaccines in development? Design: Cross-sectional online survey administered through GfK’s KnowledgePanel in 2015. Analysis completed in 2020. Subjects: Nationally representative sample of Black and White American adults (n = 1,643). Measures: Willingness to accept a novel vaccine was measured on a 4-point Likert scale. Independent variables included demographics (e.g. age, race, gender) and measures of vaccine hesitancy, trust, and the “Three C’s” of vaccine confidence, complacency, and convenience. Analysis: Exploratory analysis including descriptive statistics and regression modeling. Results: Acceptability varied from 77% for a cancer vaccine to 55% for an obesity vaccine. White race, male gender, older age, having a chronic health condition, and higher socioeconomic status were associated with higher acceptability. Higher vaccine confidence and lower vaccine hesitancy were predictors for acceptability. Conclusion: The success of a vaccine depends on widespread public acceptance. Vaccine hesitancy may hinder acceptance of future vaccines, with significant differences by demographics. Future social science research is necessary to better understand and address vaccine hesitancy.

show abstract

Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications

Cited by 22 publications

References 28 publications

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Acceptability of a Hypothetical Zika Vaccine among Women from Colombia and Spain Exposed to ZIKV: A Qualitative Study

Willingness of Black and White Adults to Accept Vaccines in Development: An Exploratory Study Using National Survey Data

Contact Info

Product

Resources

About